# Acarbose (With Meals) - Clinical Longevity Review & Consensus Audit

> **Consensus Verdict**: Acarbose (Carbohydrate Amylase Blocker)Acarbose operates distinctly from AMPK activators by functioning as an alpha-glucosidase inhibitor in the gastrointestinal tract. By competitively binding to carbohydrate amylase enzymes, it delays the digestion of complex carbohydrates, completely blunting the postprandial glucose and insulin spikes that contribute to advanced glycation end-products (AGEs) and vascular endothelial damage16. Dosed at 50mg-100mg with the first bite of a carbohydrate-heavy meal, acarbose effectively traps glucose in the physical digestive tract, providing a profound longevity benefit that has been consistently validated by the National Institute on Aging's Interventions Testing Program (ITP) in robust lifespan extension trials18.

## 1. Executive Summary & Scores
- **Longevity Evidence Score**: **83/100**
- **Evidence Quality Tier**: **bronze**
- **Human Clinical Evidence Strength**: 71/100
- **Primary Longevity Classification**: other
- **Safety Margin Score**: 84/100 (Higher is safer)
- **Time Burden**: ~15 minutes/day
- **Estimated Monthly Cost**: inexpensive
- **Adherence Friction**: 3/10 (Lower is easier to sustain)

---

## 2. Biological Mechanisms of Action
Acarbose (Carbohydrate Amylase Blocker)Acarbose operates distinctly from AMPK activators by functioning as an alpha-glucosidase inhibitor in the gastrointestinal tract. By competitively binding to carbohydrate amylase enzymes, it delays the digestion of complex carbohydrates, completely blunting the postprandial glucose and insulin spikes that contribute to advanced glycation end-products (AGEs) and vascular endothelial damage16. Dosed at 50mg-100mg with the first bite of a carbohydrate-heavy meal, acarbose effectively traps glucose in the physical digestive tract, providing a profound longevity benefit that has been consistently validated by the National Institute on Aging's Interventions Testing Program (ITP) in robust lifespan extension trials18.

---

## 3. Canonical Longevity Vector Impacts (The 8 Longevity Pillars)
- **Metabolic Flexibility & Glycemic Control**: **78/100** [Rank #41 of 129 in Metabolic] - Effect: Improves peripheral insulin sensitivity and AMPK signaling
    - Mechanism: Activates hepatic and muscular AMPK phosphorylation to facilitate glucose uptake.

---

## 4. Practical Protocol & Administration Guidelines
- **Standard Clinical Dosage**: 500 mg
- **Recommended Timing**: Pre-Meal / With Main Meal
- **Administration Type**: prescription_supported
- **Recommended Biomarkers to Monitor**: digestive_comfort, energy, satiety, brain_fog, metabolic_health

---

## 5. Safety, Contraindications & Drug Interactions
- **Contraindications**: Inflammatory bowel disease, Severe renal impairment, Gastrointestinal obstruction
- **Safety Profile**: moderate_risk - Well tolerated within physiological ranges.

---

## 6. Peer-Reviewed Human Clinical Trials & Key PMIDs
1. **Acarbose for prevention of type 2 diabetes mellitus: the STOP-NIDDM randomised trial** [PMID: 12086760]
   - Link: https://pubmed.ncbi.nlm.nih.gov/12086760/
2. **Acarbose increases postprandial anodal glucagon-like peptide 1 (GLP-1) concentration in patients with type 2 diabetes** [PMID: 15717873]
   - Link: https://pubmed.ncbi.nlm.nih.gov/15717873/
3. **Acarbose treatment and the risk of developing dementia in patients with type 2 diabetes: a retrospective nationwide cohort study** [PMID: 31801736]
   - Link: https://pubmed.ncbi.nlm.nih.gov/31801736/
4. **Targeting AMPK in Metabolic Disease and Aging** [PMID: 32060683]
   - Link: https://pubmed.ncbi.nlm.nih.gov/32060683/
5. **Acarbose, 17-alpha-Estradiol, and Rapamycin Increase Lifespan in Genetically Heterogeneous Mice: The NIA ITP Experience** [PMID: 24227383]
   - Link: https://pubmed.ncbi.nlm.nih.gov/24227383/

---

## 7. Canonical Citation & Web Verification
- **Official Web Review**: [Acarbose (With Meals) on LongevityReviews](https://longevityreviews.org/modalities/acarbose)
- **Last Evidence Calibration**: 2026-06-06
- **Review Policy**: 0% sponsored placements, independent peer-reviewed consensus.